{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shi YF"],"funding":["National Natural Science Foundation of China"],"pagination":["555"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7376040"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(7)"],"pubmed_abstract":["Bcl-2 inhibitors display an effective activity in acute myeloid leukemia (AML), but its clinical efficacy as a monotherapy was limited in part owing to failure to target other antiapoptotic Bcl-2 family proteins, such as Mcl-1. In this context, the combination strategy may be a promising approach to overcome this barrier. Here, we report the preclinical efficacy of a novel strategy combining ABT-199 with triptolide (TPL), a natural product extracted from a traditional Chinese medicine, in AML. Combination treatment exhibited markedly increased cytotoxicity in leukemic cells irrespective of p53 status while largely sparing normal cells of the hematopoietic lineage. Moreover, co-administration of ABT-199 with TPL dramatically suppressed leukemia progression as well as prolonged animal surviv"],"journal":["Cell death & disease"],"pubmed_title":["Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway."],"pmcid":["PMC7376040"],"funding_grant_id":["81800163","81770126","81570156","81770161"],"pubmed_authors":["Liu L","Yuan DL","Shi YF","Lin ZJ","He LL","Xu B","Deng MM","Carter BZ","Fang ZH","Ye J"],"additional_accession":[]},"is_claimable":false,"name":"Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.","description":"Bcl-2 inhibitors display an effective activity in acute myeloid leukemia (AML), but its clinical efficacy as a monotherapy was limited in part owing to failure to target other antiapoptotic Bcl-2 family proteins, such as Mcl-1. In this context, the combination strategy may be a promising approach to overcome this barrier. Here, we report the preclinical efficacy of a novel strategy combining ABT-199 with triptolide (TPL), a natural product extracted from a traditional Chinese medicine, in AML. Combination treatment exhibited markedly increased cytotoxicity in leukemic cells irrespective of p53 status while largely sparing normal cells of the hematopoietic lineage. Moreover, co-administration of ABT-199 with TPL dramatically suppressed leukemia progression as well as prolonged animal surviv","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-06-04T07:58:07.612Z","creation":"2025-04-06T12:08:49.126Z"},"accession":"S-EPMC7376040","cross_references":{"pubmed":["32699295"],"doi":["10.1038/s41419-020-02762-w"]}}